187 related articles for article (PubMed ID: 9205982)
21. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease].
Aranda-Verástegui F; Alberú J; Soto-Ramírez LE; González-Aguirre H; Muñoz Trejo T; Mancilla E; Díliz H; Correa-Rotter R; Sierra-Madero J
Rev Invest Clin; 2002; 54(3):198-203. PubMed ID: 12183888
[TBL] [Abstract][Full Text] [Related]
22. Extended ganciclovir prophylaxis in lung transplantation.
Perreas KG; McNeil K; Charman S; Sharples LD; Wreghitt T; Wallwork J
J Heart Lung Transplant; 2005 May; 24(5):583-7. PubMed ID: 15896756
[TBL] [Abstract][Full Text] [Related]
23. Increased risk of breakthrough infection among cytomegalovirus donor-positive/recipient-negative kidney transplant recipients receiving lower-dose valganciclovir prophylaxis.
Stevens DR; Sawinski D; Blumberg E; Galanakis N; Bloom RD; Trofe-Clark J
Transpl Infect Dis; 2015 Apr; 17(2):163-73. PubMed ID: 25661673
[TBL] [Abstract][Full Text] [Related]
24. Acyclovir versus valganciclovir for preventing cytomegalovirus infection in intermediate-risk liver transplant recipients.
McKeen JT; Tsapepas DS; Li H; Anamisis A; Martin ST
Prog Transplant; 2015 Mar; 25(1):39-44. PubMed ID: 25758799
[TBL] [Abstract][Full Text] [Related]
25. Impact of targeted oral ganciclovir prophylaxis for transplant recipients of livers from cytomegalovirus-seropositive donors.
Shah T; Lai WK; Mutimer D
Transpl Infect Dis; 2005 Jun; 7(2):57-62. PubMed ID: 16150091
[TBL] [Abstract][Full Text] [Related]
26. Increased incidence of cytomegalovirus infection in high-risk liver transplant recipients receiving valganciclovir prophylaxis versus ganciclovir prophylaxis.
Shiley KT; Gasink LB; Barton TD; Pfeiffenberger P; Olthoff KM; Blumberg EA
Liver Transpl; 2009 Aug; 15(8):963-7. PubMed ID: 19642123
[TBL] [Abstract][Full Text] [Related]
27. Long-term ganciclovir prophylaxis for successful prevention of primary cytomegalovirus (CMV) disease in CMV-seronegative liver transplant recipients with CMV-seropositive donors.
Seu P; Winston DJ; Holt CD; Kaldas F; Busuttil RW
Transplantation; 1997 Dec; 64(11):1614-7. PubMed ID: 9415569
[TBL] [Abstract][Full Text] [Related]
28. Monitoring of cytomegalovirus disease after heart transplantation: persistence of anti-cytomegalovirus IgM antibodies.
Iberer F; Halwachs-Baumann G; Rödl S; Pleisnitzer A; Wasler A; Auer T; Petutschnigg B; Müller H; Tscheliessnigg K; Wilders-Truschnig M
J Heart Lung Transplant; 1994; 13(3):405-11. PubMed ID: 8061015
[TBL] [Abstract][Full Text] [Related]
29. Long-term results of CMV hyperimmune globulin prophylaxis in 377 heart transplant recipients.
Kocher AA; Bonaros N; Dunkler D; Ehrlich M; Schlechta B; Zweytick B; Grimm M; Zuckermann A; Wolner E; Laufer G
J Heart Lung Transplant; 2003 Mar; 22(3):250-7. PubMed ID: 12633691
[TBL] [Abstract][Full Text] [Related]
30. Comparison of intravenous ganciclovir and cytomegalovirus hyperimmune globulin pre-emptive treatment in cytomegalovirus-positive heart transplant recipients.
Vrtovec B; Thomas CD; Radovancevic R; Frazier OH; Radovancevic B
J Heart Lung Transplant; 2004 Apr; 23(4):461-5. PubMed ID: 15063406
[TBL] [Abstract][Full Text] [Related]
31. Cytomegalovirus transmission in pediatric renal transplant recipients during the window period.
Gangopadhyay S; Rampersaud H; Pelletier JP; Herman L; Goldstein S; Upadhyay K
Pediatr Transplant; 2016 Feb; 20(1):172-7. PubMed ID: 26691349
[TBL] [Abstract][Full Text] [Related]
32. Prophylaxis of cytomegalovirus disease in mismatched patients after heart transplantation using combined antiviral and immunoglobulin therapy.
Czer LS; Ruzza A; Vespignani R; Rafiei M; Pixton JR; Awad M; De Robertis M; Wong AV; Trento A
Transplant Proc; 2011 Jun; 43(5):1887-92. PubMed ID: 21693295
[TBL] [Abstract][Full Text] [Related]
33. Prophylaxis of primary cytomegalovirus disease in renal transplant recipients. A trial of ganciclovir vs immunoglobulin.
Conti DJ; Freed BM; Gruber SA; Lempert N
Arch Surg; 1994 Apr; 129(4):443-7. PubMed ID: 8154971
[TBL] [Abstract][Full Text] [Related]
34. Delay of CMV infection in high-risk CMV mismatch lung transplant recipients due to prophylaxis with oral ganciclovir.
Palmer SM; Grinnan DC; Diane Reams B; Steele MP; Messier RH; Duane Davis R
Clin Transplant; 2004 Apr; 18(2):179-85. PubMed ID: 15016133
[TBL] [Abstract][Full Text] [Related]
35. Management of human cytomegalovirus infection and disease after allogeneic bone marrow transplantation.
Stocchi R; Ward KN; Fanin R; Baccarani M; Apperley JF
Haematologica; 1999 Jan; 84(1):71-9. PubMed ID: 10091394
[TBL] [Abstract][Full Text] [Related]
36. Incidence and clinical features of ganciclovir-resistant cytomegalovirus disease in heart transplant recipients.
Li F; Kenyon KW; Kirby KA; Fishbein DP; Boeckh M; Limaye AP
Clin Infect Dis; 2007 Aug; 45(4):439-47. PubMed ID: 17638191
[TBL] [Abstract][Full Text] [Related]
37. Valganciclovir as treatment for cytomegalovirus disease in solid organ transplant recipients.
Len O; Gavaldà J; Aguado JM; Borrell N; Cervera C; Cisneros JM; Cuervas-Mons V; Gurguí M; Martin-Dávila P; Montejo M; Muñoz P; Bou G; Carratalà J; Torre-Cisneros J; Pahissa A;
Clin Infect Dis; 2008 Jan; 46(1):20-7. PubMed ID: 18171208
[TBL] [Abstract][Full Text] [Related]
38. [The significance of risk-adapted antiviral prophylaxis and modern virus diagnosis for organ survival after kidney transplantation].
Fricke L; Steinhoff J; Hartwig-Weber I; Bein G
Dtsch Med Wochenschr; 1997 May; 122(18):565-71. PubMed ID: 9190308
[TBL] [Abstract][Full Text] [Related]
39. Pre-emptive intravenous ganciclovir versus valganciclovir prophylaxis for de novo cytomegalovirus-seropositive kidney-transplant recipients.
Weclawiak H; Kamar N; Mengelle C; Esposito L; Mohamed AO; Lavayssiere L; Ribes D; Cointault O; Nogier MB; Cardeau-Desangles I; Izopet J; Rostaing L
Transpl Int; 2010 Oct; 23(10):1056-64. PubMed ID: 20477997
[TBL] [Abstract][Full Text] [Related]
40. Use of combination cytomegalovirus immune globulin plus ganciclovir for prophylaxis in CMV-seronegative liver transplant recipients of a CMV-seropositive donor organ: a multicenter, open-label study.
Snydman DR; Falagas ME; Avery R; Perlino C; Ruthazer R; Freeman R; Rohrer R; Fairchild R; O'Rourke E; Hibberd P; Werner BG
Transplant Proc; 2001 Jun; 33(4):2571-5. PubMed ID: 11406251
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]